Compare Aterian Inc (ATER) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aterian Inc vs Novavax Inc — how do they compare? Aterian Inc trades at $0.48 (market cap $5.32M), while Novavax Inc trades at $7.93 (market cap $1.31B). The key difference: Novavax Inc is far larger — about 246.2× Aterian Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Aterian Inc nearer its low. Which is the better fit depends on your goals.
| ATER | NVAX | |
|---|---|---|
Market Cap | $5.32M | $1.31B |
Sector | Consumer Cyclical | Health |
52-Week High | $1.39 | $11.19 |
52-Week Low | $0.36 | $6.22 |
Enterprise Value | $5.90M | $889.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aterian (ATER) trades at $0.48, down 2.72% on the day, with a bearish technical signal. The company reported a net loss of -$18.98M in 2025, though it has beaten EPS estimates in recent quarters. Recent news highlights a pending asset sale that could return $0.85–$1.14 per share to stockholders, subject to a special meeting vote.
The outlook hinges on the asset sale approval, offering potential upside, but ongoing operational losses and negative cash flow pose significant risks. Analyst sentiment is split evenly between Buy and Hold, reflecting uncertainty around the company's restructuring and future profitability.
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aterian Inc
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products, and consumer electronics. It has various owned and operated brands include Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. The company generates revenue through the online sales of various consumer products that are sold online.
Read more on ATER →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
